Search results
Results from the WOW.Com Content Network
OpenBiome is a nonprofit health research organization based in Massachusetts accelerating research on the human microbiome. They partner with leading researchers, clinicians and innovators to advance and ensure access to novel and affordable microbiome therapeutics.
Design of engineered live bacterial therapeutics [1]. Bacterial therapy is the therapeutic use of bacteria to treat diseases.Bacterial therapeutics are living medicines, and may be wild type bacteria (often in the form of probiotics) or bacteria that have been genetically engineered to possess therapeutic properties that is injected into a patient.
The second phase, known as the Integrative Human Microbiome Project (iHMP) launched in 2014 with the aim of generating resources to characterize the microbiome and elucidating the roles of microbes in health and disease states. The program received $170 million in funding by the NIH Common Fund from 2007 to 2016. [2]
Drug Price Competition and Patent Term Restoration Act; Long title: An Act to amend the Federal Food, Drug, and Cosmetic Act to revise the procedures for new drug applications, to amend title 35, United States Code, to authorize the extension of the patents for certain regulated products, and for other purposes.
The Health Impact Fund is intended to address the problems with an uncomplemented pharmaceutical patent system. The Health Impact Fund uses market forces to create incentives to develop medicines for typically neglected diseases and to distribute these medicines at low prices all over the world. [3]
Funding for this award was received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers.
The five-year project, best characterized as a feasibility study with a budget of $115 million, tested how changes in the human microbiome are associated with human health or disease. [85] The Earth Microbiome Project (EMP) is an initiative to collect natural samples and analyze the microbial community around the globe.
“We proved efficacy against a robust controlled human infection using our first-generation norovirus construct and identified important immune markers that track with norovirus protection,” said James F. Cummings, MD, Vaxart’s Chief Medical Officer. “Our second-generation constructs induced stronger immune responses in preclinical models.